A Chinese pharmaceutical company said Wednesday it had agreed to buy at least 100 million doses of the coronavirus vaccine from German company BioNTech, subject to Beijing approving its use.
China has been rapidly developing its own COVID-19 vaccine candidates and ramping up production facilities, but local firms have also been partnering with foreign developers to supply the world’s most populous country.
Shanghai Fosun Pharmaceutical Group said its subsidiary had entered into an agreement with the German firm aimed at ensuring “an adequate supply” of vaccines in China, adding it will make an initial payment of 125 million euros ($152 million) before year-end for 50 million doses.
Fosun Pharma said it would pay the remaining 125 million euros after receiving authorisation to commercialise the German vaccine in mainland China.
The agreement did not detail when the remaining 50 million doses would arrive.
Pfizer and BioNTech’s mRNA vaccine has already been approved for emergency use in countries such as the US, the UK and Singapore.
Its vaccine is based on cutting-edge technology that uses synthetic versions of molecules called messenger RNA to hack into human cells, and effectively turn them into vaccine-making factories.
Beijing has five vaccines in the final stages of development, saying at least a million people were to receive a jab after vaccine candidates were approved for emergency use.
China has been inking agreements to supply millions of doses of Chinese-made vaccines to other countries after largely bringing the outbreak under control at home.
On Tuesday, health officials in one county of northern Heilongjiang province—where officials have been battling a small number of cases—said they would start offering COVID-19 vaccine doses to the general public.
The jabs wil cost 420 yuan ($64), but the statement did not clarify which vaccine was being offered.
Three of China’s five vaccine products that are in the final stages of development use an inactivated form of the novel coronavirus to boost immunity.
Fosun Pharma is majority-owned by Fosun International, a Chinese conglomerate that owns France-based resort giant Club Med and travel firm Thomas Cook.
Follow the latest news on the coronavirus (COVID-19) outbreak
© 2020 AFP
China’s Fosun Pharma to import 100 million BioNTech vaccine doses (2020, December 16)
retrieved 16 December 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- Health Tips Brushing For Too Long Is Dangerous Know How To Clean Teeth - January 28, 2021
- Mexico’s new daily record of almost 28,000 coronavirus cases - January 28, 2021
- Health Tips Morning Walk In Winter Is Not Good For Health - January 28, 2021
- Reversing Prediabetes Linked to Fewer Heart Attacks, Strokes - January 28, 2021
- First hybrid gene therapy shows early promise in treating long QT syndrome - January 28, 2021
- हर महिला आर्थिक रूप से सशक्त हो - January 28, 2021
- It Is Very Important For You To Do These Two Things For Better Results Of Corona Vaccine - January 28, 2021
- How Do You Treat and Repair an Umbilical Hernia? - January 28, 2021
- Enhanced recovery efforts for cesarean delivery reduce need for opioids by 80% - January 28, 2021
- Children’s Author Precious Adesuwa Releases New Book that Teaches Patience - January 28, 2021